The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
NCT00988988 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2023-08-23
Summary
Participants with multiple sclerosis that are currently treated with glatiramer acetate (GA, Copaxone®) injections and have redness, pain, swelling, itching or a lump at the injection site will be recruited to examine histamine response of three topical treatments to reduce these symptoms.
Conditions
Interventions
- DRUG
-
AGEE cream
AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
- DRUG
-
1% Steroid Cream
comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
- DRUG
-
topical placebo cream with no active ingredients
Cream to be applied immediately after injection and repeated as needed.
Sponsors & Collaborators
-
Teva Branded Pharmaceutical Products R&D, Inc.
collaborator INDUSTRY -
University of Nebraska
lead OTHER
Principal Investigators
-
Mary Filipi, PhD, APRN · University of Nebraska
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2012-08-03
- Completion
- 2012-08-03
More Related Trials
-
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
NCT01454791 ·Status: COMPLETED ·Phase: PHASE4
-
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
NCT00001669 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
NCT00856635 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086 ·Status: COMPLETED
-
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
NCT00337779 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01578785 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
NCT02308670 ·Status: COMPLETED
-
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
NCT02212886 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
NCT00203073 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Multiple Sclerosis With Copaxone and Albuterol
NCT00039988 ·Status: COMPLETED ·Phase: NA
-
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
NCT03209479 ·Status: COMPLETED
-
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
NCT00203112 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
NCT00986960 ·Status: WITHDRAWN ·Phase: PHASE2
-
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
NCT01456416 ·Status: COMPLETED
-
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
NCT01067521 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426 ·Status: COMPLETED ·Phase: PHASE3
-
GSK2018682 FTIH in Healthy Volunteers
NCT01387217 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00468611 ·Status: TERMINATED ·Phase: PHASE3
-
Alternative Treatment Paradigm for Natalizumab Trial
NCT01710228 ·Status: WITHDRAWN ·Phase: PHASE2
-
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00097760 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
NCT04121221 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
NCT04121468 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
NCT00910598 ·Status: UNKNOWN ·Phase: PHASE4